

Horizon Europe Programme

Standard Application Form (HE PCP)

Application form (Part A)
Project proposal – Technical description (Part B)

Version 2.0
26 May 2021

Application form (Part A)

Structure of the Proposal

The proposal contains two parts:

- **Part A** of the proposal **is generated by the IT system. It is based on the information entered by the participants through the submission system in the Funding & Tenders Portal.** The participants can update the information in the submission system at any time before final submission.

- **Part B** of the proposal is the narrative part that includes three sections that each correspond to an evaluation criterion. Part B needs to be uploaded as a PDF document following the templates downloaded by the applicants in the submission system for the specific call or topic. The templates for a specific call may slightly differ from the example provided in this document.

The electronic submission system is an online wizard that guides you step-by-step through the preparation of your proposal. The submission process consists of 6 steps:

- Step 1: Logging in the Portal
- Step 2: Select the call, topic and type of action in the Portal
- Step 3: Create a draft proposal: Title, acronym, summary, main organisation and contact details
- Step 4: Manage your parties and contact details: add your partner organisations and contact details.
- Step 5: Edit and complete web forms for proposal part A and upload proposal part B
- Step 6: Submit the proposal

- **Instructions and footnotes in green will not appear in the text generated by the IT system.**
- **For options *[*in square brackets*]*: the option that applies will be automatically shown in the IT system (Part A) or included in the template of Part B offered by the IT system or you must select the appropriate value from a predefined list.**
- **For fields in [grey in square brackets] (even if they are part of an option as specified in the previous item): enter the appropriate data in the IT system.**
- **Data in coloured fields will be prefilled by the IT tool.**

HISTORY OF CHANGES		
Version	**Publication date**	**Changes**
1.0	07.05.2021	▪ Initial version
		▪

Application Forms

Please check our wiki for help on navigating the form.

Horizon Europe

Application forms (Part A)

Topic:

Type of action:

Type of Model Grant Agreement:

Proposal number:

Proposal acronym:

Table of contents

The forms must be filled in for each proposal using the templates available in the Submission System. Some data fields in the forms are pre-filled based on the previous steps in the Submission wizard.

1 – General information

Section 1 provides basic data on the proposal. It can be filled in by contacts of the coordinator. Other participants may view this section only. Read-only parts are marked in blue.

Topic	Type of action
Call	Type of Model Grant Agreement

Acronym	*Acronym is mandatory*
Proposal title	*Max 200 characters (with spaces). Must be understandable for non-specialists in your field.*
	Note that for technical reasons, the following characters are not accepted in the Proposal Title and will be removed: < > " &
Duration in months	*Estimated duration of the project in full months.*
Fixed keyword	
Fixed keyword	
Free keywords	*Enter any words you think give extra detail of the scope of your proposal (max 200 characters with spaces).*

Abstract

The abstract should provide the reader with a clear understanding of the objectives of the proposal, how they will be achieved, and their relevance to the Work Programme. This summary will be used as the short description of the proposal in the evaluation process and in communications to the programme management committees and other interested parties. It must therefore be short and precise and should not contain confidential information. Use plain typed text, avoiding formulas and other special characters. If the proposal is written in a language other than English, please include an English version of this abstract in the Part B (technical description) of the proposal.

Has this proposal (or a very similar one) been submitted in the past 2 years in response to a call for proposals under any EU programme, including the current call? *A `similar' proposal or contract is one that differs from the current one in minor ways, and in which some of the present consortium members are involved.*	○ Yes	○ No
Please give the proposal reference or contract number	XXXXX-X	

Declarations

These declarations can be filled in by any coordinator contact(s). All declarations are mandatory.

1) We declare to have the explicit consent of all applicants on their participation and on the content of this proposal.	☐
2) We confirm that the information contained in this proposal is correct and complete and that none of the project activities have started before the proposal was submitted (unless explicitly authorised in the call conditions).	☐
3) We declare: – to be fully compliant with the eligibility criteria set out in the call – not to be subject to any exclusion grounds under the EU Financial Regulation 2018/1046 – to have the financial and operational capacity to carry out the proposed project.	☐
4) We acknowledge that all communication will be made through the Funding & Tenders Portal electronic exchange system and that access and use of this system is subject to the Funding & Tenders Portal Terms & Conditions.	☐
5) We have read, understood and accepted the Funding & Tenders Portal Terms & Conditions and Privacy Statement that set out the conditions of use of the Portal and the scope, purposes, retention periods, etc. for the processing of personal data of all data subjects whose data we communicate for the purpose of the application, evaluation, award and subsequent management of our grant, prizes and contracts (including financial transactions and audits).	☐
6) We declare that the proposal complies with ethical principles (including the highest standards of research integrity as set out in the ALLEA European Code of Conduct for Research Integrity, as well as applicable international and national law, including the Charter of Fundamental Rights of the European Union and the European Convention on Human Rights and its Supplementary Protocols. Appropriate procedures, policies and structures are in place to foster responsible research practices, to prevent questionable research practices and research misconduct, and to handle allegations of breaches of the principles and standards in the Code of Conduct.	☐
7) We declare that the proposal has an exclusive focus on civil applications (activities intended to be used in military application or aiming to serve military purposes cannot be funded). If the project involves dual-use items in the sense of Regulation 428/2009, or other items for which authorisation is required, we confirm that we will comply with the applicable regulatory framework (e.g. obtain export/import licences before these items are used).	☐
8) We confirm that the activities proposed do not – aim at human cloning for reproductive purposes; – intend to modify the genetic heritage of human beings which could make such changes heritable (with the exception of research relating to cancer treatment of the gonads, which may be financed), or – intend to create human embryos solely for the purpose of research or for the purpose of stem cell procurement, including by means of somatic cell nuclear transfer. – lead to the destruction of human embryos (for example, for obtaining stem cells) These activities are excluded from funding.	☐
9) We confirm that for activities carried out outside the Union, the same activities would have been allowed in at least one EU Member State	☐
10) *[Additional option for LUMP SUM Grants:* For Lump Sum Grants with a detailed budget table: We understand and accept that the EU lump sum grants must be reliable proxies for the actual costs of a project and confirm that the detailed budget for the proposal has been established in accordance with our usual cost accounting practices and in compliance with the basic eligibility conditions for EU actual cost grants (see *AGA — Annotated Grant Agreement, art 6*) and exclude costs that are ineligible under the Programme. Purchases and subcontracting costs must be done taking into	☐

account best value for money and must be free of conflict of interest.]	

The coordinator is only responsible for the information relating to their own organisation. Each applicant remains responsible for the information declared for their organisation. If the proposal is retained for EU funding, they will all be required to sign a declaration of honour.

False statements or incorrect information may lead to administrative sanctions under the EU Financial Regulation.

2 – Participants

List of participating organisations

#	Participating Organisation Legal Name	Country
1		
2		
3		

Coordinator contacts have the rights to:

- *add, delete, edit and re-order partners in the consortium*
- *add, delete, edit and re-order contact points for those organisations*
- *edit all sections of the administrative forms*
- *upload, delete, view and download Part B and Annexes (when required for the call)*
- *submit the proposal*

Participant contacts may:

- *view all the information in this screen, but not edit it*
- *edit only the section for their organisation in the administrative forms (including budget)*
- *view the entire administrative forms*
- *view/download the Part B and other Annexes*

You can manage the list of organisations and access rights of persons at Step 4 of the submission process. You may identify and give access to as many contact persons of the selected organisations as you wish. The identification is based upon the e-mail address of the person. When you add a contact person, you will be prompted to supply the contact details: name, e-mail, phone.

Person in charge of the proposal (main contact person): Each organisation needs to have one main contact person identified; the main contact person will have to fill in full contact details in the administrative form. The 'Main Contact Person' for the coordinating organisation (Participant no. 1) will become the primary contact person for the Services. Other contact persons may also be identified and may receive read-only or full access rights. Contact persons with full access rights of the coordinator (Participant no. 1) will be called 'Coordinator contacts' in the Funding & Tenders Portal, while for the other participants 'Participant Contacts'; contact persons with read-only rights will be called 'Team Members'. Other contact persons are listed with basic details in the administrative form.

Access rights: The main contact person and contact persons of the coordinator with full access rights have the same level of rights: they can manage the list of participants and contacts, edit any part of the administrative part of the proposal and upload any attachments (eg. Part B - technical description), and submit the proposal. Contact persons with read-only rights can only view/download the information. Participant contacts with full access rights can only edit their section of the administrative form and view all proposal data.
Access rights can be revoked by the Coordinating Organisation contacts. The person who created the proposal cannot be deleted.

Invitation: All contacts will receive an e-mail and a notification to the Portal about the invitation to the proposal upon saving the data at Step 4 of the submission process.

Organisation data

The section shows the administrative data of the participating organisation as registered and/or validated in the central registry of organisations of the European Commission, linked to the given PIC number. Data in blue is read-only, modification is not possible in the proposal forms. For more information on how to modify this information, please visit the online manual on the participant register.

PIC ***Legal name***

Short name

Address of the organisation

Street

Town

Postcode

Country

Webpage

Specific legal statuses

Read more about legal statuses.

Public ..... unknown Legal person ..... unknown

Non-profit ..... unknown

International organisation..... unknown

International organisation of European interest..... unknown

Secondary or Higher education establishment..... unknown

Research organisation..... unknown

SME status

The enterprise data of the organisation is taken from the Participant Register. Changes to the self-declared or self-assessed SME data can be performed by the self-registrant or by the LEAR (Legal Entity Appointed Representative) in the Participant Register.

SME self declared status ..... unknown

SME self-assessment ..... unknown

SME validation sme ..... unknown

Based on the above details of the Participant Registry the organisation is not an SME (small- and medium-sized enterprise) for the call.

Departments carrying out the proposed work

The information serves mainly statistical purposes. For determining the eligibility of the proposal, the official address of the organisation is taken into account.

Department 1

Department name		☐ not applicable
	☐ Same as organisation address	
Street	*Please enter street name and number*	
Town		
Postcode		
Country		

Links with other participants

Please indicate if there are dependencies with other participants of the proposal.
Two participants (legal entities) are dependent on each other where there is a controlling relationship between them:
** A legal entity is under the same direct or indirect control as another legal entity;or*
** A legal entity directly or indirectly controls another legal entity;or*
** A legal entity is directly or indirectly controlled by another legal entity.Control:*

Legal entity A controls legal entity B if:
** A, directly or indirectly, holds more than 50% of the nominal value of the issued share capital or a majority of the voting rights of the shareholders or associates of B, or*
** A, directly or indirectly, holds in fact or in law the decision-making powers in B.*

The following relationships between legal entities shall not in themselves be deemed to constitute controlling relationships:
(a) the same public investment corporation, institutional investor or venture-capital company has a direct or indirect holding of more than 50 % of the nominal value of the issued share capital or a majority of voting rights of the shareholders or associates;
(b) the legal entities concerned are owned or supervised by the same public body.

Type of link	***Participant***	
*[*Same group*]* *[*Controls*]* *[*Is controlled by*]*	*Select one participant from the list of participants*	

Main contact person

This will be the person the EU services will contact concerning this proposal (e.g. for additional information, invitation to hearings, sending of evaluation results, convocation to start grant preparation). The data in blue is read-only. Details (name, first name and e-mail) of Main Contact persons should be edited in step 'Participants' of the submission wizard.

Title Gender ○ Woman ○ Man ○ Non binary

First name Last name

E-mail

Position in org. *Please indicate the position of the person*

Department ☐ Same as organisation

☐ Same as organisation address

Street

Town Post code

Country

Website

Phone 1 Phone 2

Other contact persons

First name	Last name	e-mail	Phone

Researchers involved in the proposal

Include only the researchers involved in the proposal, (see below definition of 'researcher'). You do not need to include in the table the identity of other persons involved in the proposal who are not researchers.

'Researchers are professionals engaged in the conception or creation of new knowledge. They conduct research and improve or develop concepts, theories, models, techniques instrumentation, software or operational methods. (Frascati Manual 2015)'

Include also person in charge of the proposal if a researcher.

Title	First Name	Last Name	Gender	Nationality	E-mail	Career stage[1]	Role of researcher (in the project)	Reference Identifier	Type of identifier
			*[*Woman*]* *[*Man*]* *[*Non-binary*]*			*[*Category A – Top grade researcher*]* *[*Category B – Senior researcher*]* *[*Category C – Recognised researcher*]* *[*Category D – First stage researcher*]*	*[*Leading*]* *[*Team member*]*		*[*ORCID*]* *[*Researcher Id*]* *[*Other - specify*]*

[1] Career stages as defined in Frascati 2015 manual:
Category A – Top grade researcher: the single highest grade/post at which research is normally conducted. Example: 'Full professor' or 'Director of research'.
Category B – Senior researcher: Researchers working in positions not as senior as top position but more senior than newly qualified doctoral graduates (IsCED level 8). Examples: 'associate professor' or 'senior researcher' or 'principal investigator'.
Category C – Recognised researcher: the first grade/post into which a newly qualified doctoral graduate would normally be recruited. Examples: 'assistant professor', 'investigator' or 'post-doctoral fellow'.
Category D – First stage researcher: Either doctoral students at the IsCED level 8 who are engaged as researchers, or researchers working in posts that do not normally require a doctorate degree. Examples: 'PhD students' or 'junior researchers' (without a PhD).

Role of participating organisation in the project *Applicants may select more than one option.*	
Project management	☐
Communication, dissemination and engagement	☐
Provision of research and technology infrastructure	☐
Co-definition of research and market needs	☐
Civil society representative	☐
Policy maker or regulator, incl. standardisation body	☐
Research performer	☐
Technology developer	☐
Testing/validation of approaches and ideas	☐
Prototyping and demonstration	☐
IPR management incl. technology transfer	☐
Public procurer of results	☐
Private buyer of results	☐
Finance provider (public or private)	☐
Education and training	☐
Contributions from the social sciences or/and the humanities	☐
Other Specify (50 character limit):	☐

List of up to 5 publications, widely-used datasets, software, goods, services, or any other achievements relevant to the call content.

Type of achievement	**Short description**
*[*Publication*]* *[*Dataset*]* *[*Software*]* *[*Good*]* *[*Service*]* *[*Other achievement*]*	Key elements of the achievement, including a short qualitative assessment of its impact and (where available) its digital object identifier (DOI) or other type of persistent identifier (PID). Publications, in particular journal articles, are expected to be open access. Datasets are expected to be FAIR and 'as open as possible, as closed as necessary'.

List of up to 5 most relevant previous projects or activities, connected to the subject of this proposal

Name of Project or Activity	Short description

Description of any significant infrastructure and/or any major items of technical equipment, relevant to the proposed work

Name of infrastructure or equipment	Short description

Gender equality plan

Having a gender equality plan is an eligibility criterion for Public bodies, Higher education establishments and Research organisations from Member States and Associated Countries. Be aware that if the proposal is selected, having a Gender Equality Plan will be necessary before the grant agreement signature (applicable on calls with deadlines in 2022 and beyond). Does the organisation have a Gender Equality Plan (GEP) covering the elements listed below? **Minimum process-related requirements (building blocks) for a GEP** – **Publication:** formal document published on the institution's website and signed by the top management – **Dedicated resources:** commitment of human resources and gender expertise to implement it. – **Data collection and monitoring:** sex/gender disaggregated data on personnel (and students for establishments concerned) and annual reporting based on indicators. – **Training:** Awareness raising/trainings on gender equality and unconscious gender biases for staff and decision-makers. **Content-wise, recommended areas** to be **covered** and addressed via concrete measures and targets are: ○ work-life balance and organisational culture; ○ gender balance in leadership and decision-making; ○ gender equality in recruitment and career progression; ○ integration of the gender dimension into research and teaching content; ○ measures against gender-based violence including sexual harassment.	○ Yes	○ No

3 – Budget for the proposal

Please read carefully the following instructions before filling in the budget table.

In PCP actions, there are two types of eligible costs: the 'PCP procurement costs' and 'non-PCP procurement costs'. Please note that:

- The 'PCP procurement costs' includes only the costs that the buyers group estimates to spend on the PCP procurement to buy R&D services from providers on the market (also called the PCP contractors below).

- The 'additional costs', i.e. the' costs for those cost categories other than the cost category D.5 PCP/PPI procurement costs, are eligible only up to 50% of the total estimated eligible costs of the action. The 'PCP procurement costs' (in column D.5) must thus amount to minimum 50% of the total estimated costs of the action (in column h) in the budget table, and all 'additional costs' can thus amount to maximum 50% of the total estimated costs of the action.

- 'additional costs' include all costs needed for the preparation, implementation and follow-up of the PCP procurement (including testing of solutions by the lead procurer, members of the buyers group, or other end-users) and further activities to embed the PCP into a wider set of demand-side activities. This includes for example dissemination of results, removing obstacles for introducing the solutions in the market (e.g. contribution to standardisation, regulation and certification), awareness raising, experience sharing/training, preparing further cooperation among stakeholders and procurers for future PCPs or PPIs. All types of 'additional costs' must be included under the cost categories in the budget table that are not the category D.5 PCP procurement costs: for example, personnel costs of the lead procurer, buyers group and other consortium participants under column A, subcontracting costs (e.g. for design of the website/publicity campaign to promote the procurement) under column B, purchase costs (e.g. for travel tickets, equipment needed by the buyers group to test solutions delivered by the providers that win the PCP contracts) under column C, financial support to third parties (e.g. to award a prize to the solution provider(s) that performed best in the PCP) under column D1 and internally invoices goods and services under column D2. Other cost categories D.3, D.4 and D.6 to D.11 are not applicable to PCP actions.

A PCP action can support the implementation, under coordination of a lead procurer, of one joint PCP procurement implemented by a transnational buyers' group.

In both cases, there are two options for allocating the PCP procurement costs:
- Option 1: If the consortium chooses to have all selected PCP contractors paid by the lead procurer, then only the lead procurer must complete category D.5 and enter there the total estimated PCP procurement costs,
- Option 2: If the consortium chooses to have all selected PCP contractors paid pro rata by each procurer in the buyers group according to the share of the individual contribution of each procurer to the total PCP procurement costs of the project, then each procurer in the buyer group must enter in category D.5 his individual share of the total estimated PCP procurement costs of the project.

The estimated PCP procurement costs entered in D.5 shall include the related duties, taxes and charges, such as non-deductible, non-refundable value added tax (VAT). Different duties, taxes and charges (in particular also a different VAT rate) may apply, depending on whether the consortium chooses to have all selected PCP tenderers paid by the lead procurer or paid pro rata by each procurer in the buyers group. It is up to the consortium to verify the applicable duties, taxes and charges, including VAT rates, with the responsible national authorities of the countries of the lead procurer and/or the buyers group, depending on whether option 1 or 2 is chosen.

Please note that the lead procurer and members of the buyers group must be beneficiaries. Participants that are not beneficiaries (e.g. affiliated entities, associated partners, third parties giving in-kind contributions to the action, recipients of financial support to third parties and subcontractors) must therefore not enter any costs under category D.5 PCP procurement costs.

			Estimated expenditure								Estimated income					
											Requested EU contribution			Revenues	Other sources of financing		
			Estimated eligible costs								EU contribution to eligible costs						
No	Participant name	Country	A. Personnel costs/€ (a1)	B. Subcontracting costs/€ (b)	C. Purchase costs			D. Other cost categories	E. Indirect costs/€ (e) = 25% * [(a1) + (c1) + (c2) + (c3) + (d7)]	Total eligible costs (h) = (a1) + (b) + (c1) + (c2) + (c3) + (d) + (e)	Funding rate (U)	Maximum EU contribution to eligible costs (l) = (U) * (h)	Requested EU contribution to eligible costs/€ (Requested grant amount) (m) (n)	Income generated by the action (o)	Financial contributions (q)	Own resources (r)	Total estimated income (s)=(n)+(o)+(p)+(q) + (r)
					C.1 Travel and subsistence/€ (c1)	C.2 Equipment/€ (c2)	C.3 Other goods, works and services /€ (c3)	D.X [specific cost category] /€ (dx)									
1	Participant 1	NL															
2	Participant 2	LB															
	Affiliated Entity	LB															
3	Participant 3	DE															
	Associated Partner	AR															
Total																	

Possible 'Other cost categories' for Horizon Europe

			Estimated project expenditure									
			Estimated eligible costs									
			D. Other cost categories									
No	Participant name	Country	D.1 Financial support to third parties (Actual costs) (d1)	D.2 Internally invoiced goods and services (Unit costs - usual accounting practices) (d2)	[D.3 Transnational access to research infrastructures (Unit costs) (d3)]	[D.4 Virtual access to research infrastructures (Unit costs) (d4)]	[D.5 PCP/PPI procurement costs (Actual costs) (d5)]	[D.6 Euratom Cofund staff mobility costs (Unit costs) (d6)]	[D.7 ERC additional funding (Actual costs) (d7)]	[D.8 ERC additional funding (subcontracting, FSTP and internally invoiced goods and services) (Actual costs) (d8)]		
1	Participant 1	NL										
2	Participant 2	LB										
	Affiliated Entity	LB										
3	Participant 3	DE										
	Associated Partner	AR										
Total												

4 – Ethics and Security

Ethics issues table

This table should be completed as an essential part of your proposal. Please go through the table and indicate which elements concern your proposal by answering 'Yes' or 'No'. If you answer 'Yes' to any of the questions,

- *indicate in the adjacent box at which page in your technical description further information relating to that ethics issue can be found, and*
- *provide additional information on that ethics issue in the Ethics Self-Assessment section.*

For more information on each of the ethics issues and how to address them, including detailed legal references, see the guidelines 'How to Complete your Ethics Self-Assessment'.

1. HUMAN EMBRYONIC STEM CELLS AND HUMAN EMBRYOS			Page
Does this activity involve Human Embryonic Stem Cells (hESCs)?		○ Yes ○ No	
If **YES**:	Will they be directly derived from embryos within this project?	○ Yes ○ No	
	Are they previously established cells lines?	○ Yes ○ No	
	Are the cell lines registered in the European registry for human embryonic stem cell lines?	○ Yes ○ No	
Does this activity involve the use of human embryos?		○ Yes ○ No	
If **YES**:	Will the activity lead to their destruction?	○ Yes ○ No	
2. HUMANS			Page
Does this activity involve human participants?		○ Yes ○ No	
If **YES**:	Are they volunteers for nonmedical studies (e.g. social or human sciences research)?	○ Yes ○ No	
	Are they healthy volunteers for medical studies?	○ Yes ○ No	
	Are they patients for medical studies?	○ Yes ○ No	
	Are they potentially vulnerable individuals or groups?	○ Yes ○ No	
	Are they children/minors?	○ Yes ○ No	
	Are they other persons unable to give informed consent?	○ Yes ○ No	
Does this activity involve interventions (physical also including imaging technology, behavioural treatments, etc.) on the study participants?		○ Yes ○ No	
If **YES**:	Does it involve invasive techniques?	○ Yes ○ No	
	Does it involve collection of biological samples?	○ Yes ○ No	

Does this activity involve conducting a clinical study as defined by the Clinical Trial Regulation (EU 536/2014)? (using pharmaceuticals, biologicals, radiopharmaceuticals, or advanced therapy medicinal products)		○ Yes ○ No	
If **YES**:	Is it a clinical trial?	○ Yes ○ No	
	Is it a low-intervention clinical trial?	○ Yes ○ No	
3. HUMAN CELLS / TISSUES (not covered by section 1)			Page
Does this activity involve the use of human cells or tissues?		○ Yes ○ No	
If **YES**:	Are they human embryonic or foetal cells or tissues?	○ Yes ○ No	
	Are they available commercially?	○ Yes ○ No	
	Are they obtained within this project?	○ Yes ○ No	
	Are they obtained from another project, laboratory or institution?	○ Yes ○ No	
	Are they obtained from biobank?	○ Yes ○ No	
4. PERSONAL DATA			Page
Does this activity involve processing of personal data?		○ Yes ○ No	
If **YES**:	Does it involve the processing of special categories of personal data (e.g.: sexual lifestyle, ethnicity, genetic, biometric and health data, political opinion, religious or philosophical beliefs)?	○ Yes ○ No	
	If **YES**: Does it involve processing of genetic, biometric or health data?	○ Yes ○ No	
	Does it involve profiling, systematic monitoring of individuals, or processing of large scale of special categories of data or intrusive methods of data processing (such as, surveillance, geolocation tracking etc.)?	○ Yes ○ No	
Does this activity involve further processing of previously collected personal data (including use of preexisting data sets or sources, merging existing data sets)?		○ Yes ○ No	
Is it planned to export personal data from the EU to non-EU countries?		○ Yes ○ No	
If **YES**:	Specify the type of personal data and countries involved:		
Is it planned to import personal data from non-EU countries into the EU or from a non-EU country to another non-EU country?		○ Yes ○ No	
If **YES**:	Specify the type of personal data and countries involved		

Does this activity involve the processing of personal data related to criminal convictions or offences?		○ Yes ○ No	
5. ANIMALS			Page
Does this activity involve animals?		○ Yes ○ No	
If **YES**:	Are they vertebrates?	○ Yes ○ No	
	Are they non-human primates (NHP)?	○ Yes ○ No	
	Are they genetically modified?	○ Yes ○ No	
	Are they cloned farm animals?	○ Yes ○ No	
	Are they endangered species?	○ Yes ○ No	
6. NON-EU COUNTRIES			Page
Will some of the activities be carried out in non-EU countries?		○ Yes ○ No	
If **YES**:	Specify the countries:		
In case non-EU countries are involved, do the activities undertaken in these countries raise potential ethics issues?		○ Yes ○ No	
If **YES**:	Specify the countries:		
Is it planned to use local resources (e.g. animal and/or human tissue samples, genetic material, live animals, human remains, materials of historical value, endangered fauna or flora samples, etc.)?		○ Yes ○ No	
Is it planned to import any material (other than data) from non-EU countries into the EU or from a non-EU country to another non-EU country? For data imports, see section 4.		○ Yes ○ No	
If **YES**:	Specify material and countries involved:		
Is it planned to export any material (other than data) from the EU to non-EU countries? For data exports, see section 4.		○ Yes ○ No	
If **YES**:	Specify material and countries involved:		
Does this activity involves low and/or lower-middle income countries? (if yes, detail the benefit-sharing actions planned in the self-assessment)		○ Yes ○ No	
Could the situation in the country put the individuals taking part in the activity at risk?		○ Yes ○ No	
7. ENVIRONMENT, HEALTH and SAFETY			Page

Does this activity involve the use of substances or processes that may cause harm to the environment, to animals or plants (during the implementation of the activity or further to the use of the results, as a possible impact)?	○ Yes ○ No	
Does this activity deal with endangered fauna and/or flora / protected areas?	○ Yes ○ No	
Does this activity involve the use of substances or processes that may cause harm to humans, including those performing the activity (during the implementation of the activity or further to the use of the results, as a possible impact)?	○ Yes ○ No	
8. ARTIFICIAL INTELLIGENCE		Page
Does this activity involve the development, deployment and/or use of Artificial Intelligence? (if yes, detail in the self-assessment whether that could raise ethical concerns related to human rights and values and detail how this will be addressed).	○ Yes ○ No	
9. OTHER ETHICS ISSUES		Page
Are there any other ethics issues that should be taken into consideration?	○ Yes ○ No	
Please specify: (Maximum number of characters allowed: 1000)		

I confirm that I have taken into account all ethics issues above and that, if any ethics issues apply, I will complete the ethics self-assessment as described in the guidelines 'How to Complete your Ethics Self-Assessment'. ☐

ETHICS SELF-ASSESSMENT

If you have entered any issues in the ethics issue table, you must perform an ethics self-assessment in accordance with the guidelines "How to Complete your Ethics Self-Assessment" and complete the table below.

Ethical dimension of the objectives, methodology and likely impact
Explain in detail the identified issues in relation to: – objectives of the activities (e.g. study of vulnerable populations, etc.) – methodology (e.g. clinical trials, involvement of children, protection of personal data, etc.) – the potential impact of the activities (e.g. environmental damage, stigmatisation of particular social groups, political or financial adverse consequences, misuse, etc.)
Compliance with ethical principles and relevant legislations
Describe how the issue(s) identified in the ethics issues table above will be addressed in order to adhere to the ethical principles and what will be done to ensure that the activities are compliant with the E U / national legal and ethical requirements of the country or countries where the tasks are to be carried out. It is reminded that for **activities performed in a non-EU countries**, they should also be allowed in at least one EU Member State.

Security issues table

Please indicate, by answering Yes or No to all of the questions in the below table, if the proposed activity will use and/or generate information which might raise security concerns. If an answer is Yes, then indicate in the adjacent box at which page in your full proposal further information relating to that issue can be found.

1. EU classified information (EUCI)[2]			Page
Does this activity involve information and/or materials requiring protection against unauthorised disclosure (EUCI)?		○ Yes ○ No	
If **YES**:	Is the activity going to use classified information as background[3] information?	○ Yes ○ No	
	Is the activity going to generate EU classified foreground[4] information as results?	○ Yes ○ No	
Does this activity involve non-EU countries?		○ Yes ○ No	
If **YES**:	Do participants from non-EU countries need to have access to EUCI?	○ Yes ○ No	
	Do the non-EU countries concerned have a security of information agreement with the EU	○ Yes ○ No	
2. MISUSE			**Page**
Does this activity have the potential for misuse of results?		○ Yes ○ No	
If **YES**:	Does the activity provide knowledge, materials and technologies that could be channelled into crime and/or terrorism?	○ Yes ○ No	
	Could the activity result in the development of chemical, biological, radiological or nuclear (CBRN) weapons and the means for their delivery?	○ Yes ○ No	
3. OTHER SECURITY ISSUES			**Page**
Does this activity involve information and/or materials subject to national security restrictions?		○ Yes ○ No	
If yes, please specify: *(Maximum number of characters allowed: 1000)*			

[2] According to the Commission Decision (EU, Euratom) 2015/444 of 13 March 2015 on the security rules for protecting EU classified information, "European Union classified information (EUCI) means any information or material designated by an EU security classification, the unauthorised disclosure of which could cause varying degrees of prejudice to the interests of the European Union or of one or more of the Member States".

[3] Classified background information is information that is already classified by a country and/or international organisation and/or the EU and is going to be used by the project. In this case, the project must have in advance the authorisation from the originator of the classified information, which is the entity (EU institution, EU Member State, third state or international organisation) under whose authority the classified information has been generated.

[4] EU classified foreground information is information (documents/deliverables/materials) planned to be generated by the project and that needs to be protected from unauthorised disclosure. The originator of the EUCI generated by the project is the European Commission.

Are there any other security issues that should be taken into consideration?	○ Yes ○ No	
If yes, please specify: (Maximum number of characters allowed: 1000)		

5 – Other questions

Additional declaration

The coordinator confirms that the self-check has been performed by minimum two partners in the project - including the lead procurer and minimum two partners in the buyers group - that they are compliant with the definition of contracting authority or contracting entity as defined in the EU public procurement directives. The coordinator confirms the willingness of the partners to provide, in case the proposal is positively evaluated, selfdeclarations to the EC on this point.	○ Yes ○ No

[Additional modular extension for Calls with clinical trials: Essential information to be provided for proposals including clinical trials / studies / investigations

Clinical study means, for the purpose of this document, any systematic prospective or retrospective collection and analysis of health data obtained from individual patients or healthy persons in order to address scientific questions related to the understanding, prevention, diagnosis, monitoring or treatment of a disease, mental illness, or physical condition. It includes but it is not limited to clinical studies as defined by Regulation 536/2014 (on medicinal products), clinical investigation and clinical evaluation as defined by Regulation 2017/745 (on medical devices), performance study and performance evaluation as defined by Regulation 2017/746 (on in vitro diagnostic medical devices.

Are clinical studies / trials / investigations included in the work plan of this project?	○ Yes ○ No

Please upload the dedicated annex 'Essential information for clinical studies / trials / investigations' (a Word template is provided under 'download templates' in the up-load section for Part B and Annexes).

This document should include the relevant information of each clinical study / trial / investigation included in the work plan of this project.

Please give a short title, an acronym or a unique identifier to each clinical study / trial / investigation, to be used as a reference / identifier in the other parts of the proposal	Add Remove

]

Project proposal – Technical description (Part B)

Structure of the Proposal

The proposal contains two parts:

- **Part A** of the proposal **is generated by the IT system. It is based on the information entered by the participants through the submission system in the Funding & Tenders Portal.** The participants can update the information in the submission system at any time before final submission.

- **Part B** of the proposal is the narrative part that includes three sections that each correspond to an evaluation criterion. Part B needs to be uploaded as a PDF document following the templates downloaded by the applicants in the submission system for the specific call or topic. The templates for a specific call may slightly differ from the example provided in this document.

The electronic submission system is an online wizard that guides you step-by-step through the preparation of your proposal. The submission process consists of 6 steps:

- Step 1: Logging in the Portal
- Step 2: Select the call, topic and type of action in the Portal
- Step 3: Create a draft proposal: Title, acronym, summary, main organisation and contact details
- Step 4: Manage your parties and contact details: add your partner organisations and contact details.
- Step 5: Edit and complete web forms for proposal part A and upload proposal part B
- Step 6: Submit the proposal

HISTORY OF CHANGES		
Version	**Publication date**	**Changes**
1.0	07.05.2021	▪ Initial version
1.1	25.05.2021	▪ Addition of a table in section 3.1 about in-kind contributions

Proposal template Part B: technical description

(for full proposals: single stage submission procedure and 2nd stage of a two-stage submission procedure)

This template is to be used in a single-stage submission procedure or at the 2nd stage of a two-stage submission procedure.

The structure of this template must be followed when preparing your proposal. It has been designed to ensure that the important aspects of your planned work are presented in a way that will enable the experts to make an effective assessment against the evaluation criteria. Sections 1, 2 and 3 each correspond to an evaluation criterion.

Please be aware that proposals will be evaluated as they were submitted, rather than on their potential if certain changes were to be made. This means that only proposals that successfully address all the required aspects will have a chance of being funded. There will be no possibility for significant changes to content, budget and consortium composition during grant preparation.

⚠ **Page limit**: The title, list of participants and sections 1, 2 and 3, together, should not be longer than 45 pages. All tables, figures, references and any other element pertaining to these sections must be included as an integral part of these sections and are thus counted against this page limit. The number of pages included in each section of this template is only **indicative**.

The page limit will be applied automatically. **At the end of this document you can see the structure of the actual proposal that you need to submit, please remove all instruction pages that are watermarked.**

If you attempt to upload a proposal longer than the specified limit before the deadline, you will receive an automatic warning and will be advised to shorten and re-upload the proposal. After the deadline, excess pages (in over-long proposals/applications) will be automatically made invisible, and will not be taken into consideration by the experts. The proposal is a self-contained document. Experts will be instructed to ignore hyperlinks to information that is specifically designed to expand the proposal, thus circumventing the page limit.

Please, do not consider the page limit as a target! It is in your interest to keep your text as concise as possible, since experts rarely view unnecessarily long proposals in a positive light.

⚠ The following formatting conditions apply.

The reference font for the body text of proposals is Times New Roman (Windows platforms), Times/Times New Roman (Apple platforms) or Nimbus Roman No. 9 L (Linux distributions).

The use of a different font for the body text is not advised and is subject to the cumulative conditions that the font is legible and that its use does not significantly shorten the representation of the proposal in number of pages compared to using the reference font (for example with a view to bypass the page limit).

The minimum font size allowed is 11 points. Standard character spacing and a minimum of single line spacing is to be used. This applies to the body text, including text in tables.

Text elements other than the body text, such as headers, foot/end notes, captions, formula's, may deviate, but must be legible.

The page size is A4, and all margins (top, bottom, left, right) should be at least 15 mm (not including any footers or headers).

DEFINITIONS	
Critical risk	A critical risk is a plausible event or issue that could have a high adverse impact on the ability of the project to achieve its objectives. Level of likelihood to occur (Low/medium/high): The likelihood is the estimated probability that the risk will materialise even after taking account of the mitigating measures put in place. Level of severity (Low/medium/high): The relative seriousness of the risk and the significance of its effect.
Deliverable	A report that is sent to the Commission or Agency providing information to ensure effective monitoring of the project. There are different types of deliverables (e.g. a report on specific activities or results, data management plans, ethics or security requirements).
Impacts	Example: *The deployment of the advanced forecasting system enables each airport to increase maximum passenger capacity by 15% and passenger average throughput by 10%, leading to a 28% reduction in infrastructure expansion costs.*
Milestone	Control points in the project that help to chart progress. Milestones may correspond to the achievement of a key result, allowing the next phase of the work to begin. They may also be needed at intermediary points so that, if problems have arisen, corrective measures can be taken. A milestone may be a critical decision point in the project where, for example, the consortium must decide which of several technologies to adopt for further development. The achievement of a milestone should be verifiable.
Objectives	The goals of the work performed within the project, in terms of its research and innovation content. This will be translated into the project's results. These may range from tackling specific research questions, demonstrating the feasibility of an innovation, sharing knowledge among stakeholders on specific issues. The nature of the objectives will depend on the type of action, and the scope of the topic.
Outcomes	The expected effects, over the medium term, of projects supported under a given topic. The results of a project should contribute to these outcomes, fostered in particular by the dissemination and exploitation measures. This may include the uptake, diffusion, deployment, and/or use of the project's results by direct target groups. Outcomes generally occur during or shortly after the end of the project. Example: *9 European airports adopt the advanced forecasting system demonstrated during the project.*
Pathway to impact	Logical steps towards the achievement of the expected impacts of the project over time, in particular beyond the duration of a project. A pathway begins with the projects' results, to their dissemination, exploitation and communication, contributing to the expected outcomes in the work programme topic, and ultimately to the wider scientific, economic and societal impacts of the work programme destination.
Research output	Results generated by the action to which access can be given in the form of scientific publications, data or other engineered outcomes and processes such as software, algorithms, protocols and electronic notebooks.
Results	What is generated during the project implementation. This may include, for example, know-how, innovative solutions, algorithms, proof of feasibility, new business models, policy recommendations, guidelines, prototypes, demonstrators, databases and datasets, trained researchers, new infrastructures, networks, etc. Most project results (inventions, scientific works, etc.) are 'Intellectual Property', which may, if appropriate, be protected by formal 'Intellectual

	Property Rights'. Example: *Successful large-scale demonstrator: trial with 3 airports of an advanced forecasting system for proactive airport passenger flow management.*
Technology Readiness Level	See Work Programme General Annexes B

⚠ *Fill in the title of your proposal below.*

TITLE OF THE PROPOSAL

⚠ *The consortium members are listed in part A of the proposal (application forms). A summary list should also be provided in the table below.*

List of participants

Participant No. *	Participant organisation name	Country
1 (Coordinator)		
2		
3		

* Please use the same participant numbering and name as that used in the administrative proposal forms.

1. Excellence

Excellence – aspects to be taken into account.

- Clarity and pertinence of the objectives and the extent to which they are ambitious, and go beyond the state of the art in terms of the degree of innovation that is needed to satisfy the procurement need.
- Soundness of the proposed methodology, taking into account the underlying concepts and assumptions.

⚠ *The following aspects will be taken into account only to the extent that the proposed work is within the scope of the work programme topic.*

1.1 Objectives and ambition *[e.g. 4 pages]*

Objectives

Briefly describe the objectives of your proposed work. Why are they pertinent to the work programme topic? Are they measurable and verifiable? Are they realistically achievable?

- Describe in particular the 'common challenge' that is the proposed focus/objective for the joint PCP. The common challenge is the procurement need that is commonly identified and shared by all procurers in the buyers group of the project and that forms the object of the proposed PCP procurement. In case the common challenge consists of several facets (sub-challenges or building blocks), describe the different facets and confirm that all procurers in the buyers group share the need for all the facets.

  ⚠ *A PCP action that addresses a challenge that consists of several facets (sub-challenges or building blocks) is considered one joint PCP procurement as long as all procurers in the buyers group share the need for - and agree to procure together R&D to address - all the facets of the common challenge.*

- Describe how the common challenge addresses a concrete unmet need: describe any preparatory analysis, in particular the analysis of the procurement needs of the buyers group and the needs of other potential end-users of the innovative solutions that motivates the start of a PCP. Clarify why existing solutions do not meet the procurement need any more and new R&D is needed to address the need. Your answer could also refer to the cost / benefit analysis of the buyers group to undertake the PCP, benchmarking of solutions. Clarify also if the unmet need for innovative solutions is driven by internal motivations of the procurers to obtain quality and/or efficiency improvements in the area of public interest and/or by regulatory requirements that require the procurers to look for innovative solutions.

Ambitions / progress beyond the state-of-the art

- Describe how your project goes beyond the state-of-the-art in terms of the degree of innovation that is needed to satisfy the procurement need, and the extent the proposed work is ambitious.
- Describe how ambitious are the quality and/or efficiency improvements in public services that the PCP aims to achieve compared to the public services that are currently operated by procurers in the market. Describe how demanding is the degree of R&D that the supply side will need to perform to satisfy the procurement need and reach the quality/efficiency improvements targeted by the PCP.
- Where relevant, illustrate the advance beyond the state-of-the art by referring to products and services already available on the market. Refer to any patent or publication search carried out. In case the project intends to contribute to standardisation, certification and/or regulatory activities, illustrate the advance beyond the state-of-the art by referring to applicable standardisation, certification, regulatory initiatives.

1.2 Methodology *[e.g. 15 pages]*

- Describe and explain the **overall methodology**, including the concepts, models and assumptions that underpin your work. Explain how this will enable you to deliver your project's objectives, distinguishing as appropriate specific activities requested in the relevant section(s) of the work programme. Refer to any important challenges you may have identified in the chosen methodology and how you intend to overcome them. *[e.g. 12 pages]*

  - ⚠ *This section should be presented as a narrative. The detailed tasks and work packages are described below under 'Implementation'.*
  - ⚠ *Where relevant, include how the project methodology complies with the 'do no significant harm' principle as per Article 17 of Regulation (EU) No 2020/852 on the establishment of a framework to facilitate sustainable investment (i.e. the so-called 'EU Taxonomy Regulation'). This means that the methodology is designed in a way it is not significantly harming any of the six environmental objectives of the EU Taxonomy Regulation.*

- Confirm that the consortium will implement the PCP procurement in compliance with the specific requirements for the implementation of PCPs, defined in Work Programme General Annex H and in the Model Grant Agreement. Explain in this section mainly additional **implementation aspects specific for your project** that were not specified in the above Annex or Grant Agreement.

- Identify which beneficiary is proposed to be the **lead procurer** and which beneficiaries constitute the **buyers group** (indicate which of them are public procurers versus, if applicable, additional private or NGO type procurers that share the same procurement need). If applicable identify third parties associated to beneficiaries that are involved in carrying out the joint PCP.

  - ⚠ *The lead procurer is the procurer that is appointed by the buyers group in an action to coordinate and lead the joint PCP procurement in the name and on behalf of the buyers group.*
  - ⚠ *The buyers group is the group of procurers in an action that provides the financial commitments for undertaking together the joint PCP procurement during the action.*
  - ⚠ *Third parties providing in-kind contributions can be actively involved in carrying out the joint PCP procurement e.g. by providing test resources or equipment to the buyers group and/or lead procurer that are needed to carry out the procurement.*

- Describe the **approach for the preparation stage** of the PCP (in particular for open market consultation, the development of the common specifications and the common evaluation criteria for the joint PCP).

- Describe the **consortium's initial plans for the selection of R&D providers** for the different phases of the PCP. Indicate how the joint evaluation of offers based on best value for money award criteria will be organised (e.g. using external experts or not to assist in the evaluation of offers).

  - ⚠ *If the specific call conditions restrict participation to the PCP procurement to bidders that are established in and/or controlled from specific countries due to security reasons, impose a specific place of performance obligation or impose other requirements to safeguard EU strategic autonomy, ensure that the selection process for the PCP procurement meets these restrictions.*

- Describe clearly **the proposed set-up of the PCP process**: the expected number of phases in the PCP process, the expected duration / budget of each PCP phase, the number of R&D providers foreseen to be invited to participate in the PCP to have a good representation of possible competing solution paths, the expected maximum number of R&D providers to be selected at each phase, the expected maximum budget to be allocated per participating R&D provider at each PCP phase, etc.

  - ⚠ *Minimum three R&D providers must be selected to start the PCP, except if less than two tenderers are capable of performing the R&D services in the EU Member States or Associated Countries (for security*

contracts, this may be restricted to the Member States), then the phase 1 contracts may be awarded to a minimum of two tenderers.

⚠ *Each PCP is implemented via a framework contract that covers three specific contracts per PCP phase: solution design (phase 1), prototyping (phase 2), and original development including installation and testing of a limited volume of test series products/services in the procurers/end-users premises (phase 3). The following simplification / acceleration in the procedure may be used for PCPs that require fast deployment[1]: one specific contract may cover both the second and third PCP phase.*

- Describe briefly the **expected outcome of each PCP phase** that R&D providers are expected to achieve. Specify in particular whether the purchasing needs of the buyers group are such that **the PCP will include the purchase of R&D products resulting from the PCP or not**, and if so, for what purpose and what is the expected value of those R&D products to be procured compared to the total PCP contract value.

⚠ *Due to the definition of R&D, this possibility extends only to buying the limited set of prototypes or products that were developed / tested during the PCP (e.g. buying the source code resulting from software R&D can enable further testing and validation of the developed solutions after the PCP by the procurers), and this does not extend to 'larger quantity' production and/or supply of goods or services. The value of any supplies procured cannot exceed 50% of the total PCP contract value.*

- Describe how the **monitoring of the R&D providers** will be organised (which project partners are involved) during the PCP to ensure execution of the R&D according to plan. Describe also the **approach to test / validate / compare in the last PCP phase the performance of different competing solutions in real-life operational conditions of the targeted public service** against the desired functional / performance requirements that are jointly defined by the procurers in the buyers group, in order to verify the fitness for purpose in view of potential conversion into permanent service of the solutions.

- Describe, if applicable, proposed **additional activities for removing barriers for wide market introduction of the targeted innovative solutions** (e.g. contribution to standardisation, regulation, certification, awareness raising and experience sharing, preparing the ground for cooperation in future PCPs or PPIs).

- Identify any **other national or international activities or initiatives** (e.g. other on-going or planned PCP or PPI projects, other research and innovation, standardisation, certification, regulation or policy activities) whose results will feed into the project, and how that link will be established; *[e.g. 1 pages]*

- For topics where the work programme indicates the need for the integration of **social sciences and humanities**, show the role of these disciplines in the project or provide a justification if you consider that these disciplines are not relevant to your proposed project. *[e.g. 1/2 page]*

- Describe how the **gender dimension** (i.e. sex and/or gender analysis) is taken into account in the project's research and innovation content *[e.g. 1/2 page].*

⚠ *Note: This section is mandatory except for topics which have been identified in the work programme as not requiring the integration of the gender dimension into the R&I content of the PCP procurement.*

⚠ *Remember that that this question relates to the content of the planned research and innovation activities, and not to gender balance in the teams in charge of carrying out the project.*

⚠ *Sex and gender analysis refers to biological characteristics and social/cultural factors respectively. For guidance on methods of sex / gender analysis and the issues to be taken into account, please refer to http://ec.europa.eu/research/swafs/gendered-innovations/index_en.cfm?pg=home*

[1] Especially where budgetary commitment for deployment is already available at the start of the PCP ('fast-track' PCPs).

- Explain how the choice of Open Science practices and their implementation are adapted to the nature of your work to increase the chances of the project delivering on its objectives. If you believe that none of these practices are appropriate for your project, please provide a justification here.

  ⚠ *Open Science is an approach based on open cooperative work and systematic sharing of knowledge and tools as early and widely as possible in the process. Open science practices include early and open sharing of research (for example through preregistration, registered reports, pre-prints, or crowd-sourcing); research output management; measures to ensure reproducibility of research outputs; providing open access to research outputs (such as publications, data, software, models, algorithms, and workflows); participation in open peer-review; and involving all relevant knowledge actors including citizens, civil society and end users in the co-creation of R&I agendas and contents (such as citizen science).*

- Research **data management and management of other research outputs:** Applicants generating/collecting data and/or other research outputs (except for publications) during the project must provide maximum 1/2 page on how the data/ research outputs will be managed in line with the FAIR principles (Findable, Accessible, Interoperable, Reusable), addressing the following (the description should be specific to your project): *[e.g. 1/2 page]*

  Types of data/research outputs (e.g. experimental, observational, images, text, numerical) and their estimated size; if applicable, combination with, and provenance of, existing data.

  Findability of data/research outputs: Types of persistent and unique identifiers (e.g. digital object identifiers) and trusted repositories that will be used.

  Accessibility of data/research outputs: IPR considerations and timeline for open access (if open access not provided, explain why); provisions for access to restricted data for verification purposes.

  Interoperability of data/research outputs: Standards, formats and vocabularies for data and metadata.

  Reusability of data/research outputs: Licenses for data sharing and re-use (e.g. Creative Commons, Open Data Commons); availability of tools/software/models for data generation and validation/interpretation /re-use.

  Curation and storage/preservation costs; person/team responsible for data management and quality assurance.

⚠ *Proposals selected for funding under Horizon Europe will need to develop a detailed data management plan (DMP) for making their data/research outputs findable, accessible, interoperable and reusable (FAIR) as a deliverable by month 6 and revised towards the end of a project's lifetime.*

⚠ *For guidance on open science practices and research data management, please refer to the relevant section in the HE Programme Guide on the Funding & Tenders Portal.*

2. Impact

Impact – aspects to be taken into account.

- Credibility of the pathways to achieve the expected outcomes and impacts specified in the work programme.
- Suitability and quality of the measures to maximise expected outcomes and impacts, as set out in the dissemination and exploitation* plan, including communication activities.

* For PCP actions and PPI actions, the exploitation of results by the beneficiaries means primarily the usage of the innovative solutions by the procurers/end-users, as the manufacturing and sales of the innovative solutions is performed by the suppliers of the solutions which are not beneficiaries but subcontractors.

The results of your project should make a contribution to the expected outcomes set out for the work programme topic over the medium term, and to the wider expected impacts set out in the 'destination' over the longer term.

In this section you should show how your project could contribute to the outcomes and impacts described in the work programme, the likely scale and significance of this contribution, and the measures to maximise these impacts.

2.1 Project's pathways towards impact *[e.g. 4 pages]*

- Provide a **narrative** explaining how the project's results are expected to make a difference in terms of impact, beyond the immediate scope and duration of the project. The narrative should include the components below, tailored to your project.

  (a) Describe the unique contribution your project results would make towards (1) the **outcomes** specified in this topic in the work progamme, and (2) the **wider impacts**, in the longer term, specified in the respective destinations in the work programme.

  - *Be specific, referring to the effects of your project, and not R&I in general in this field.*
  - *State the target groups that would benefit. Even if target groups are mentioned in general terms in the work programme, you should be specific here, breaking target groups into particular interest groups or segments of society relevant to this project.*
  - *The outcomes and impacts of your project may be:*
    - *Scientific, e.g. contributing to specific scientific advances, across and within disciplines, creating new knowledge, reinforcing scientific equipment and instruments, computing systems (i.e. research infrastructures);*
    - *Economic/tecnological, e.g. strenghtening the competitive position of businesses, speeding up the modernisation of the public sector, improving EU resilience and strategic autonomy, by bringing new products, services, business processes to the market, acceleration the adoption of innovative solutions, increasing efficiency, decreasing costs, increasing profits, triggering further financial investments in business growth, removing barriers to market entry by contributing for example to standards' setting, certification of solutions etc.*
    - *Societal, e.g. decreasing CO_2 emissions, decreasing avoidable mortality, improving policies and decision making, raising consumer awareness.*

  Only include such outcomes and impacts where your project would make a significant and direct contribution. Avoid describing very tenuous links to wider impacts. However, include any potential negative environmental outcome or impact of the project including when expected results are brought at scale (such as at commercial level). Where relevant, explain how the potential harm can be managed.

(b) Describe any **requirements and potential barriers** - arising from factors beyond the scope and duration of the project - that may determine whether the desired outcomes and impacts are achieved. These may include, for example, other R&I work within and beyond Horizon Europe; regulatory environment; targeted markets; user behaviour. Indicate if these factors might evolve over time. Describe any mitigating measures you propose, within or beyond your project, that could be needed should your assumptions prove to be wrong, or to address identified barriers.

⚠ *Note that this does not include the critical risks inherent to the management of the project itself, which should be described below under 'Implementation'.*

(c) Give an indication of the **scale and significance** of the project's contribution to the expected outcomes and impacts, should the project be successful. Provide quantified estimates where possible and meaningful.

⚠ *'Scale' refers to how widespread the outcomes and impacts are likely to be. For example, in terms of the size of the target group, or the proportion of that group, that should benefit over time; 'Significance' refers to the importance, or value, of those benefits. For example, number of additional healthy life years; efficiency savings in energy supply.*

⚠ *Explain your baselines, benchmarks and assumptions used for those estimates. Wherever possible, quantify your estimation of the effects that you expect from your project. Explain assumptions that you make, referring for example to any relevant studies or statistics. Where appropriate, try to use only one methodology for calculating your estimates: not different methodologies for each partner, region or country (the extrapolation should preferably be prepared by one partner).*

⚠ *Your estimate must relate to this project only - the effect of other initiatives should not be taken into account.*

2.2 Measures to maximise impact - Dissemination, exploitation and communication *[e.g. 5 pages, including section 2.3]*

- Describe the planned measures to maximise the impact of your project by providing a first version of your '**plan for the dissemination and exploitation including communication activities**'. Describe the dissemination, exploitation and communication measures that are planned, and the target group(s) addressed (e.g. scientific community, end users, financial actors, public at large).

  - Regarding **communication and dissemination**:
    - Describe in particular how the procurers will encourage Europe-wide industrial interest and involvement in the PCP. Describe how the consortium intends to maximise the interest of providers from across all Europe to participate in the open market consultation (to refine the scope of the procurement based on feedback from potential providers about ongoing industrial developments) and to send in sufficient amount of good quality offers to the PCP call for tender.
    - Describe also the proposed measures for communicating about the project results and impacts, in particular about the benefits of the innovation solutions developed during the PCP (quality / efficiency improvements obtained by procurers and new technical advances / commercialisation benefits achieved by providers).

  - Regarding **exploitation of results**:
    - Describe to what extent the consortium will provide a first customer reference to the providers participating in the PCP. Highlight in how many procurers' sites the solutions are planned to be validated/tested and deployed. Describe in particular the plans/commitments of the buyers group to deploy and to continue using innovative solutions resulting from the PCP.
    - Describe planned measures to encourage other procurers and end-users on the market to also adopt the innovative solutions. Where relevant, describe how the consortium will ensure

coherence and interoperability across borders of the different competing solutions developed during the PCP to facilitate wider uptake.

- Describe also any measures foreseen to help the providers that participate in the PCP to further commercialise results and grow their business (e.g. facilitating contacts with financial investors or other companies, joining the providers in promoting their solutions towards other customers e.g. at fairs, awarding an award to the best performing provider(s) that participate in the PCP etc.).

⚠ *Please remember that this plan is an admissibility condition, unless the work programme topic explicitly states otherwise. In case your proposal is selected for funding, a more detailed 'plan for dissemination and exploitation including communication activities' will need to be provided as a mandatory project deliverable within 6 months after signature date. This plan shall be periodically updated in alignment with the project's progress.*

⚠ *Communication[2] measures should promote the project throughout the full lifespan of the project. The aim is to inform and reach out to society and show the activities performed, and the use and the benefits the project will have for citizens and other professional end-users (e.g. other public buyers and other businesses on the market). Activities must be strategically planned, with clear objectives, start at the outset and continue through the lifetime of the project. The description of the communication activities needs to state the main messages as well as the tools and channels that will be used to reach out to each of the chosen target groups.*

⚠ *All measures should be proportionate to the scale of the project, and should contain concrete actions to be implemented both during and after the end of the project, e.g. deployment / procurement of newly developed solutions resulting from the PCP, standardisation / certification activities. Your plan should give due consideration to the possible follow-up of your project, once it is finished. In the justification, explain why each measure chosen is best suited to reach the target group addressed. Where relevant, and for innovation actions, in particular, describe the measures for a plausible path to commercialise the innovations.*

⚠ *If exploitation is expected primarily in non-associated third countries, justify by explaining how that exploitation is still in the Union's interest.*

⚠ *Describe possible feedback to policy measures generated by the project that will contribute to designing, monitoring, reviewing and rectifying (if necessary) existing policy and programmatic measures or shaping and supporting the implementation of new policy initiatives and decisions.*

- Outline your **strategy for the management of intellectual property**, foreseen protection measures, such as patents, design rights, copyright, trade secrets, etc., and how these would be used to support exploitation.

  - Confirm compliance with the specific IPR allocation requirements for PCPs defined in the General Annex H of the work programme and the PCP actions model grant agreement, that optimises:
    (1) The opportunities for providers that participate in the PCP to pursue wide exploitation of results by allocating them the ownership rights of their results, including IPRs (along with the associated responsibility to commercialise the innovative solutions developed during the PCP)
    (2) The freedom to operate of the procurers in the buyers group, by allocating them license free rights to use the results, the right to (require the providers that participate in the PCP to) license the results to other third parties, the right to require the transfer the IPR to the procurers in the buyers group in case of non-exploitation of the results or abuse of the results against public interests

[2] For further guidance on communicating EU research and innovation for project participants, please refer to the Online Manual on the Funding & Tenders Portal

Describe any additional IPR related specificities of your project: e.g. whether the project plans to allow other specific buyers outside the project to piggy-back on the results of the procurement.

- *If your project is selected, you will need an appropriate consortium agreement to manage (amongst other things) the ownership and access to key knowledge (IPR, research data etc.). A clear agreement will need to be included on how the buyers group will decide as a group about the licensing rights and the rights to require transfer of IPR. Where relevant, these aspects will allow you, collectively and individually, to pursue market opportunities arising from the project.*

- *If your project is selected, you must indicate the owner(s) of the results (results ownership list) in the final periodic report.*

2.3 Summary

Provide a summary of this section by presenting in the canvas below the key elements of your project impact pathway and of the measures to maximise its impact.

KEY ELEMENT OF THE IMPACT SECTION

SPECIFIC NEEDS	EXPECTED RESULTS	D & E & C MEASURES
What are the specific procurement needs that triggered this project? Example 1 The buyers group, a group of cities, need to become climate-neutral to reach the Green Deal objectives. Energy and transport are the biggest contributors to carbon emissions in urban areas and smart solutions are needed to reduce this. Example 2 Several bacteria have become resistant to antibiotics due to over-prescription by doctors. In order for our health systems to become more resilient to the spread of diseases caused by bacteria, the buyers group, a group of ministries, health agencies and hospitals, need new smarter antibiotics that remain effective when widely used.	What do you expect to generate by the end of the project? Example 1 **Test results demonstrate** that several newly developed AI solutions enable to speed up climate neutrality in cities. **Algorithmic model / first new products deployed:** Novel AI algorithms that predict energy usage bottlenecks and proactively optimise use of energy sources in cities. **6 cities are the first customer reference** for the suppliers that participated in the procurement, by having tested and deployed the new solution. A wider group of cities is piggy backing on the PCP to adopt the solutions also quickly after. **City staff is trained,** so they are acquainted with the AI **Publication of the key PCP results** Example 2 **Test results demonstrate** that several newly developed smarter antibiotics remain effective against bacteria. **Publication of the key PCP results** and publication of a **scientific discovery on overcoming the antibiotics resistance problem.** **First new products tested and possibly also deployed:** Large scale pilot group of first patients treated with new smart antibiotics and possibly first batch rolled out after.	What dissemination, exploitation and communication measures will you apply to the results? Example 1 **Exploitation:** Patenting the algorithmic model. Copyright on software. Search for investors to scale up market distribution. Standardising interconnections. **Dissemination to the scientific community and cities**: (Scientific) publication with the results. Participation at trade fairs and events with cities & EU city associations. **Communication towards citizens:** A demonstration in urban areas to show how the outcomes of the action are relevant to our everyday lives. Example 2 **Exploitation of the new product:** Patenting the new invention; Trademarking the new product name; Direct sales to governments, attracting investment to scale up the company from SME to unicorn, licencing to other major pharma companies. **Dissemination to scientific, health community and industry:** Participating at conferences, major health trade fairs and at EC project portfolios to disseminate the results as part of a group.

TARGET GROUPS

Who will use or further up-take the results of the project? Who will benefit from the results of the project?

Example 1

6 major European cities that formed the initial buyers group (for wider scale deployment later) **+** 10 other European cities that piggy back on the procurement to deploy the results later

Major energy producers/providers companies: Electrabel, EDF, Nuon etc

Scientific community (field of AI)

European citizens (indirect)**.**

Example 2

End-users/European citizens and medical doctors: consumers and prescribers of antibiotics.

Companies (incl. Small SMEs) that develop the new smart antibiotics and other major pharma companies: Janssen Pharmaceutica / Johnson & Johnson etc.

Scientific community (field of health).

OUTCOMES

What change do you expect to see after successful dissemination and exploitation of project results to the target group(s)?

Example 1

Up-take by cities: Wider adoption of the advanced AI solutions first by the 10 partner cities that followed the project and later by other cities across and beyond the EU.

Further uptake by traditional and renewable energy providers, possibly after **standardization** of interconnection aspects.

Several new AI solutions produced in Europe are sold.

Example 2

High use of the scientific discovery published in further R&I and exploitation activities by other researchers and companies (measured with the relative rate of citation index of project publications).

Several new smart antibiotics from different companies that are producing in Europe are sold.

Both small and major pharma companies exploit/use the new product in their manufacturing.

IMPACTS

What are the expected wider scientific, economic and societal effects of the project contributing to the expected impacts outlined in the respective destination in the work programme?

Example 1

Scientific/Technological: New breakthrough product for AI based forecasting / management of urban energy resources. Technological spin-offs to other segments.

Economic: Increased energy efficiency, optimised use of renewable energy sources, leading to cheaper solutions, stronger growth of European AI companies

Societal: climate neutrality in energy usage achievable, leading to a 58% reduction of CO2 emissions in EU cities. Citizens benefit from energy neutral city buildings etc.

Example 2

Scientific: New breakthrough scientific discovery on smart antibiotics.

Economic/Technological: A new market for smart antibiotics provided by a stronger European supply chain, increased EU strategic autonomy and decreased dependence on import from outside EU **Increased competition and resilience in the European supply chain and reinforced production of new smart antibiotics products 'in Europe'**.

Societal: Pharmacies and citizens benefit from cheaper and a more diversified set of antibiotics. Reduced spreading of diseases caused by bacteria, reduced healthcare costs, healthier citizens.

3. Quality and efficiency of the implementation

Quality and efficiency of the implementation – aspects to be taken into account

- *Quality and effectiveness of the work plan, assessment of risks, and appropriateness of the effort assigned to work packages, and the resources overall*
- *Capacity and role of each participant, and extent to which the consortium as a whole brings together the necessary expertise.*

3.1 Work plan and resources *[e.g. 14 pages – including tables]*

Regarding the work plan, please provide the following:

- brief presentation of the overall structure of the work plan;
- timing of the different work packages and their components (Gantt chart or similar);
- graphical presentation of the components showing how they inter-relate (Pert chart or similar).
- detailed work description, i.e.:
  - a list of work packages (table 3.1a);
  - a description of each work package (table 3.1b);

    Please include distinct work packages for

    - 'Preparation of the procurement' (detailing the planned activities to prepare the launch of the call for tender – such as open market consultation, preparation of common procurement specifications and joint procurement agreement – in compliance with the PCP actions and Annex H of the work programme).
    - 'Execution and follow-up of the procurement' (detailing the tendering and evaluation process that will select the best value for money offers across the different phases in compliance with the PCP actions Grant Agreement and Annex H of the work programme, how the lead procurer/buyers group will cooperate in the management of the procurement procedure, how/where the innovative solutions will be tested by which members of the buyers group, how providers that participate in the PCP will be monitored/paid by which members of the buyers group)

      ⚠ *Give full details. Base your account on the logical structure of the project and the stages in which it is to be carried out. The number of work packages should be proportionate to the scale and complexity of the project.*

      ⚠ *You should give enough detail in each work package to justify the proposed resources to be allocated and also quantified information so that progress can be monitored, including by the Commission*

      ⚠ *Resources assigned to work packages should be in line with their objectives and deliverables. You are advised to include a distinct work package on 'project management', and to give due visibility in the work plan to 'data management' 'dissemination and exploitation' and 'communication activities', either with distinct tasks or distinct work packages.*

      ⚠ *You will be required to update the 'plan for the dissemination and exploitation of results including communication activities', and a 'data management plan', (this does not apply to*

topics where a plan was not required.) This should include a record of activities related to dissemination and exploitation that have been undertaken and those still planned.

⚠ *Please make sure the information in this section matches the costs as stated in the budget table in section 3 of the application forms, and the number of person months, shown in the detailed work package descriptions.*

- a list of deliverables (table 3.1.c);
- a list of milestones (table 3.1.d);

⚠ *Every PCP action consists of a preparation stage and an execution stage, for which there are mandatory deliverables and milestones defined in Annex H of the work programme.*

For the preparation stage of the action, include the following mandatory deliverables (D)/milestones (M):

- (D) The prior information notice for the open market consultation, to be submitted to the granting authority minimum 5 days before submission for publication to OJEU at the latest 50 days before the start of the first open market consultation meeting
- By the end of the preparation stage, to be submitted to the granting authority with the second pre-financing payment request:
  - (D) A report on the outcome of the preparation phase of the procurement (including the result of the open market consultation, the prior art analysis, and any other key preparatory activities (e.g. standardization, regulatory activities) and their impact on the call for tender
  - (D) The completed call for tender documents based on the Horizon Europe PCP/PPI model contract documents, including the contract notice, invitation to tender, procurement contracts: at the latest 30 days before its submission to the OJEU
  - (M) The signed joint procurement agreement confirming the final collaboration modus, including the financial commitment of the buyers group for the PCP, and final confirmation of the lead procurer.

For the Execution stage of the action, include the following mandatory deliverables (D)/milestones (M):

- (D) A copy of the contract award notice published in TED: to be submitted to the granting authority, at the latest 48 days after the award of contracts
- At the end of the evaluation of tenders - also after the evaluations for each PCP phase - a deliverable with the following elements, to be submitted to the granting authority:
  - (D) Information on the total number of bids received (submitted using the Horizon Europe template), in particular the data on the winning tenderer(s) and abstracts of the winning tenders for publication and evaluation purposes
  - (D) Final ranking list of the selected projects, final scores and qualitative assessment per evaluation criterion for each received bid, minutes of the evaluation meeting
  - (D) Conclusions of the assessment and validation by the buyers group of the results that were achieved by each participating tenderer in the previous PCP phase (submitted using the Horizon Europe template)
- At the end of the action: (M) A demonstration to the granting authority of the developed and tested solutions that are resulting from the PCP

- a list of critical risks, relating to project implementation, that the stated project's objectives may not be achieved. Detail any risk mitigation measures. You will be able to update the list of critical risks and mitigation measures as the project progresses (table 3.1e);

Regarding the resources to be committed to the action, please provide the following:

For the 'PCP procurement costs':

- a table showing the contribution of each member of the buyer group to the total PCP procurement costs (table 3.1.f)

For the 'Additional costs' (i.e. all costs that are not the PCP procurement costs):

- a table showing number of person months required (table 3.1g);
- a table showing description and justification of subcontracting costs for each participant (table 3.1h);
- a table showing justifications for 'purchase costs' (table 3.1i) for participants where those costs exceed 15% of the personnel costs (according to the budget table in proposal part A);
- if applicable, a table showing justifications for 'other costs categories' (table 3.1j).
- if applicable, a table showing in-kind contributions from third parties (table 3.1k)

⚠ *For PCP actions, tables 3.1g, 3.1h, 3.1i, 3.1j and 3.1k only include costs that are NOT the procurement costs: Table 3.1g includes for example the person months needed by each participant to prepare, implement and follow up the procurement, to implement the project management and dissemination activities; Table 3.1h can include for example subcontracting costs for designing the website/publicity campaign to promote the PCP procurement; Table 3.1i can include for example costs incurred by the buyers group to buy test equipment (i.e. tools that the buyers group needs to test and compare on their premises the different solutions that are developed by the R&D providers that participate in the PCP); Table 3.1j can include for example internally invoiced goods and services which are provided directly for the action within the organisation of one of the buyers.*

3.2 Capacity of participants and consortium as a whole *[e.g. 3 pages]*

⚠ *The individual members of the consortium are described in a separate section under Part A. There is no need to repeat that information here.*

- Describe the consortium. How does it match the project's objectives, and bring together the necessary skills and knowledge. Include in the description affiliated entities and associated partners, if any.
- Show how the partners will have access to critical infrastructure needed to carry out the project activities.
- Describe how the members complement one another
- In what way does each of them contribute to the project? Show that each has a valid role, and adequate resources in the project to fulfil that role.
- Please be aware that in order to avoid conflicts of interest, there can be no participants in the consortium that are potential providers of solutions for the PCP (see Work Programme General Annex H).
- **Other countries and international organisations**: If one or more of the participants requesting EU funding is based in a country or is an international organisation that is not automatically eligible for such funding (entities from Member States of the EU, from Associated Countries and from one of the countries in the exhaustive list included in the Work Programme General Annexes B are automatically eligible for EU

funding), explain why the participation of the entity in question is essential to successfully carry out the project.

Tables for section 3.1

Table 3.1a: List of work packages

Work package No	Work Package Title	Lead Participant No	Lead Participant Short Name	Person-Months	Start Month	End month
				Total person-months		

Table 3.1b: Work package description

For each work package:

Work package number		**Lead beneficiary**					
Work package title							
Participant number							
Short name of participant							
Person months per participant:							
Start month				**End month**			

Objectives

Description of work (where appropriate, broken down into tasks), lead partner and role of participants

Deliverables (brief description and month of delivery)

Table 3.1c: List of Deliverables[3]

Only include deliverables that you consider essential for effective project monitoring.

Deliverable (number)	Deliverable name	Work package number	Short name of lead participant	Type	Dissemination level	Delivery date (in months)

KEY
Deliverable numbers in order of delivery dates. Please use the numbering convention <WP number>.<number of deliverable within that WP>.
For example, deliverable 4.2 would be the second deliverable from work package 4.

Type:
Use one of the following codes:

R: Document, report (excluding the periodic and final reports)
DEM: Demonstrator, pilot, prototype, plan designs
DEC: Websites, patents filing, press & media actions, videos, etc.
DATA: Data sets, microdata, etc.
DMP: Data management plan
ETHICS: Deliverables related to ethics issues.
SECURITY: Deliverables related to security issues
OTHER: Software, technical diagram, algorithms, models, etc.

Dissemination level:
Use one of the following codes:

PU – Public, fully open, e.g. web (Deliverables flagged as public will be automatically published in CORDIS project's page)
SEN – Sensitive, limited under the conditions of the Grant Agreement
Classified R-UE/EU-R – EU RESTRICTED under the Commission Decision No2015/444
Classified C-UE/EU-C – EU CONFIDENTIAL under the Commission Decision No2015/444
Classified S-UE/EU-S – EU SECRET under the Commission Decision No2015/444

Delivery date
Measured in months from the project start date (month 1)

[3] You must include a data management plan (DMP) and a 'plan for dissemination and exploitation including communication activities as distinct deliverables within the first 6 months of the project. The DMP will evolve during the lifetime of the project in order to present the status of the project's reflections on data management. A template for such a plan is available in the Online Manual on the Funding & Tenders Portal.

Table 3.1d: List of milestones

Milestone number	Milestone name	Related work package(s)	Due date (in month)	Means of verification

KEY
Due date
Measured in months from the project start date (month 1)

Means of verification
Show how you will confirm that the milestone has been attained. Refer to indicators if appropriate. For example: a laboratory prototype that is 'up and running'; software released and validated by a user group; field survey complete and data quality validated.

Table 3.1e: Critical risks for implementation

Description of risk (indicate level of (i) likelihood, and (ii) severity: Low/Medium/High)	Work package(s) involved	Proposed risk-mitigation measures

Definition critical risk:
A critical risk is a plausible event or issue that could have a high adverse impact on the ability of the project to achieve its objectives.

Level of likelihood to occur: Low/medium/high
The likelihood is the estimated probability that the risk will materialise even after taking account of the mitigating measures put in place.

Level of severity: Low/medium/high
The relative seriousness of the risk and the significance of its effect.

Table 3.1f: Total committed budget for the PCP procurement

Please complete the Table below with the individual financial commitments that each member the buyers group contributes to the total PCP procurement cost, to show the breakdown of the PCP procurement costs (that are declared in D.5 in the budget table) across the different beneficiaries that are members of the buyers group. The commitments in column (a) of the Table express the intention of the procurers in the buyers group to make available the corresponding financial resources in due course by the time the PCP procurement will be launched during the action. These are provisional commitments subject to the present proposal being selected for funding and to the successful completion of the preparation stage of the action. Via the deliverable/milestone to be submitted at the end of the preparation stage (see section 3.1), the concerned beneficiaries will provide their final

confirmation of their individual financial commitments that will be contributed to the total budget necessary to jointly finance the PCP, the total committed budget for the PCP, from which all tenderers that are selected as a result of the joint PCP call for tender will be paid by the consortium.

Participant Number / Short Name	Country	(a) EU contribution from Horizon Europe program to the PCP procurement costs [€] (min d * funding rate for PCP action)	(b) Additional contribution from participant's own resources to the PCP procurement costs [€] (max d* funding rate for PCP action)	(c) Additional EU contribution from other EU programs to the PCP procurement costs [€] (optional)	(d) Minimum total committed budget for the PCP procurement = Maximum amount of PCP procurement costs that can be eligible for funding by Horizon 2020 [€] (a + b)	(e) Maximum total committed budget for the PCP procurement [€] (a + b + c)
Total						

oflumn ()bursement rate
PCP/PPIubcontracts25252525252525252525252525252525252525252525252525252525252525252525252525252525 2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525 252525

In case there are participants that plan to mobilise additional funding from other EU programs to increase the total budget available for the PCP procurement, then please complete for those participants the column (c) with the additional contribution of these participants to the total budget for payment of the PCP contracts that is funded by other EU programs and indicate also the name of the other EU program (such as the EU Structural and Investment Funds). Please split clearly for each participant the part of the PCP procurements costs that is proposed to be funded by Horizon Europe from the other part of the PCP procurement costs that is proposed to be funded from other EU programs, in order to avoid double funding (As explained for example by ESIF regulation, it is not possible to fund one and the same expenditure incurred by the same participant by different EU programs[4]). ESIF funding can thus not be used to replace the participant's own contribution to the part of the PCP procurement costs that is funded by Horizon Europe. The same prohibition applies also in the other direction to the use of Horizon Europe funds to cover the applicant's contribution to a project funded by ESIF

[4] Article 57(9) of Council Regulation No. COM/2018/375 final - 2018/0196 on the ERDF. Article 57(9) provides that "*An operation may receive support from one or more programmes and from other Union instruments. In such cases expenditure declared in a payment application for one of the Funds shall not be declared for support from another Fund or Union instrument*". Separating PCP procurement costs funded by Horizon Europe from PCP procurement costs funded by ESIF can be implemented by requesting separate invoices for both.

Table 3.1g: Summary of staff effort

Please indicate the number of person/months over the whole duration of the planned work, for each work package, for each participant. Identify the work-package leader for each WP by showing the relevant person-month figure in bold.

	WPn	WPn+1	WPn+2	Total Person-Months per Participant
Participant Number/Short Name				
Participant Number/ Short Name				
Participant Number/ Short Name				
Total Person Months				

Table 3.1h: 'Subcontracting costs' items

For each participant describe and justify the tasks to be subcontracted (please note that core tasks of the project should not be sub-contracted).

Participant Number/Short Name		
	Cost (€)	**Description of tasks and justification**
Subcontracting		

Table 3.1i: 'Purchase costs' items (travel and subsistence, equipment and other goods, works and services)

Please complete the table below for each participant if the purchase costs (i.e. the sum of the costs for 'travel and subsistence', 'equipment', and 'other goods, works and services') exceeds 15% of the personnel costs for that participant (according to the budget table in proposal part A). The record must list cost items in order of costs and starting with the largest cost item, up to the level that the remaining costs are below 15% of personnel costs.

Participant Number/Short Name		
	Cost (€)	**Justification**
Travel and subsistence		
Equipment		
Other goods, works and services		
Remaining purchase costs (<15% of pers. Costs)		
Total		

Table 3.1j: 'Other costs categories' items (e.g. internally invoiced goods and services)

Please complete the table below for each participants that would like to declare costs under other costs categories (e.g. internally invoiced goods and services), irrespective of the percentage of personnel costs.

Participant Number/Short Name		
	Cost (€)	**Justification**
Internally invoiced goods and services		
…		

Table 3.1k: 'In-kind contributions' provided by third parties

Please complete the table below for each participants that will make use of in-kind contributions (non-financial resources made available free of charge by third parties). In kind contributions provided by third parties free of charge are declared by the participants as eligible direct costs in the corresponding cost category (e.g. personnel costs or purchase costs for equipment).

Participant Number/Short Name			
Third party name	**Category**	**Cost (€)**	**Justification**
	Select between Seconded personnel Travel and subsistence Equipment Other goods, works and services Internally invoiced goods and services		

STANDARD MODULAR EXTENSION OF PROPOSAL TEMPLATE:

1. FINANCIAL SUPPORT TO THIRD PARTIES

- **PART A: No additions**
- **PART B: Add an additional annex with information on financial support to third parties**

Financial support to third parties

⚠ *For more information on terms and conditions: see Work Programme General Annexes section B and Horizon Europe Model Grant Agreement Articles 6.2.D.1 and 9.4*

[OPTION financial support in the form of a grant:

Financial support in the form of a grant awarded after a call for proposals

Where this possibility is indicated under the relevant topic in the Work Programme and in the relevant calls for proposals, provide a description of the use of financial support to third parties. This description must address at least the following:

1. clearly detail the objectives and the results to be obtained and
2. contain the following specifications (as a minimum):
   a) the maximum amount of financial support for each third party; this amount may not exceed 60 000 EUR, unless explicitly mentioned in the work programme topic
   b) the criteria for calculating the exact amount of the financial support
   c) the different types of activity that qualify for financial support, on the basis of a closed list
   d) the persons or categories of persons that may receive financial support, and
   e) the criteria for giving financial support

Please check in the Work Programme and call for proposals if there are other conditions that apply and, if so, include them in the specifications or in any other element of the proposal as appropriate.
]

[OPTION financial support in the form of a prize:

Financial support in the form of a prize

Where this possibility is indicated under the relevant topic in the Work Programme, provide a description of the use of financial support to third parties. This description must address at least the following:

1. clearly detail the objectives and the results to be obtained and
2. contain the following specifications (as a minimum):
   a) the eligibility and award criteria
   b) the amount of the prize and
   c) the payment arrangements.

Please check in the Work Programme and the call for proposals if the are other conditions that apply and, if so, include them in the specifications or in any other element of the proposal as appropriate.
]

2. CLINICAL TRIALS

- **PART A: Additional question**
- **PART B: Add an additional annex with information on clinical trials**

3. CALLS FLAGGED AS SECURITY SENSITIVE

- **PART A: No additions**
- **Part B: Add an additional annex with information on security**